 |
 Animal Models of Inhibitors
A Q&A with David Lillicrap (Canada) and Valder Arruda (U.S.A.)
Working with animal models could lead to better pre-clinical methods of predicting inhibitor formation, providing important research support for the 10 to 15 new bleeding disorder treatments that are likely to be introduced in the next five years. More
|
|
Clinical Trial Updates
A number of important clinical trials are either underway or about to begin. Enrolling the relatively large number of patients required for each of these clinical trials is and will continue to be a challenge. More
|
|
Differential Responses to Bypassing Agents
A Q&A with Jan Astermark (Sweden)
Patient responses to the two available bypassing agents, factor VIII inhibitor bypassing activity (FEIBA) and recombinant factor VIIa (rFVIIa), are variable. More
|
|
Exploring the genetic basis of VWD
A Q&A with Paula James (Canada)
A genome-wide association study strategy for von Willebrand Disease (VWD) could yield an exponential increase in knowledge over the next several years. More
|
|
 Imaging modalities for detecting arthropathy
A Q&A with Andrea Doria (Canada)
“Health professionals can make better use of anatomic imaging techniques that are already available in our hospitals and participate in the clinical translation of new functional imaging techniques." More
|
|
Misdiagnosis of Platelet Function Disorders
A Q&A with Cathy Hayward (Canada)
Without standardization among centres, platelet disorders are both under- and over-diagnosed, leading to inconsistent treatment for a cluster of conditions that are at least as common as von Willebrand disease. More
|
|
 Models of prophylaxis in developing countries
A Q&A with Alok Srivastava (India)
Current models for prophylactic factor replacement often suggest that only those countries with clotting factor concentrate (CFC) available at more than 3 IU per capita can initiate prophylaxis. But this is not necessarily so, according to Dr. Alok Srivastava. More
|
|
Pharmacovigilance and long-term surveillance
A Q&A with Chris Ludlam (U.K.)
The development of large surveillance projects like the European Haemophilia Safety Surveillance project (EUHASS) is the latest step in fully understanding the long-term side effects of hemophilia treatment. More
|
|
Update on vCJD Transmission
The understanding that variant Creutzfeld Jacob Disease (vCJD) has a long incubation period and the confirmation that it can be transmitted through blood transfusion has prompted the United Kingdom to undertake a study to determine the prevalence of the infection in the population. More
|
|
Women with Bleeding Disorders
A Q&A with Andra James (U.S.A.)
Despite wider understanding of women’s bleeding disorders, diagnosis can still take well over a decade. More |
Building our global family by reaching out to women, children and youth and those in sub-Saharan Africa to achieve Treatment for All. The World Federation of Hemophilia (WFH) has committed to recognizing and incorporating the critical and important challenges that are faced by women with bleeding disorders within our global family.